THÔNG TIN TÀI LIỆU
Cyclooxygenase, in control of circulation, 1358 Cyclosporine, for Kawasaki syndrome, 990 CYP2C9, 1432–1434 CYP2C19, 1434 CYP2D6, 1431–1432 CYP3A, 1434 Cystic fibrosis, exercise testing in, 402 Cysts, pericardial, 1075 Cytogenetics, 56 Cytotrophoblasts, 157–158 D Dacron, 220–221 Dallas criteria, in myocarditis, 1175 Damus-Kaye-Stansel (DKS) procedure, 1280–1281, 1281–1282, 1281f Danon disease (DD), 80 hypertrophic cardiomyopathy and, 1147–1148 Daptomycin, for infective endocarditis, 1053t Data accuracy of, 410 analysis of, 410–415 plan for, 411 relationships between variables and, 411 reliability of, 410 validity of, 409–410 variables and, description of, 411 Data registries, in congenital cardiac care, 1510, 1511t–1514t Data sources, in congenital cardiac care, 1509–1510 Database, 403 DC, Dilated cardiomyopathy DCD, Donation after circulatory death DD, Danon disease Dead donor rule, in cardiac transplantation, 1476–1477 Death, of child, 1463 Decision authority, ethical issues and, 1472 Decision support tools, 1438, 1439f Decisional authority, 1469t Decision-making, shared, ethical issues and, 1471 Decreased central nervous maturity, in congenital brain disease, 1396 Deep hypothermic circulatory arrest, in cardiopulmonary bypass, 230–231 Defibrillation, 335–378 Defibrillators, 364–366 cardioverter, implantable, 366–367, 366f, 368f Delayed sternal closure, management of, in Fontan pathway, 1290 Deletion 8P23 syndrome, 1410, 1410f–1411f, 1410t Deletion 22q11.2, 1410–1411, 1411t Denominator, definition of, 173–174 Dependent variables, 410–411 Descending aorta, in diagnostic catheterization, 251 Developing heart, physiology of, 83–107, Fetal heart Development, following cardiac transplantation, 1238 Developmental care, for prematurity, 211–212 Developmental disability, genetic susceptibility to, 1397 Developmental services, for complex congenital cardiac disease, 1402, 1402b Development-specialized machinery, of cardiomyocyte, 71–77 actin and titin, 72–73 excitation and contraction, 75–77, 76f mitochondria and energy production, 74–75, 75f myosin, 71–72 sarcomere, 71, 71f troponin, 73–74 Devices, removal of, in pulmonary venous stenosis, interventional techniques for, 274–275 Dexamethasone, for antibody-mediated fetal heart disease, 143–144, 144f Dexmedetomidine, 1549 Dexrazoxane, for cancer therapy-related cardiotoxicity, 1171 Dextrocardia, 917 Dextroposition, 917 Dextroversion, 917 Diabetes, type 1, systemic arterial dysfunction and, 1371 Diabetes mellitus, cardiac involvement in, 1095–1096 Diagnosis, research studies on, critical appraisal of, 421–422 Diagnosis-based, for integrated care pathways, 1482t Diagnostic catheterization anatomic approach in, 243–252 anesthesia in, 239 angiographic evaluation in, 242–243, 243t in aorta, 251 in aortic valve apparatus, 250 in atrial septum, 245–246 in azygous vein, 244, 245f catheters for, 240 complex congenital heart lesions in, 252 in coronary arteries, 250–251 equipment for, 240 in femoral vein, 243–244 heart transplant patients in, 251–252
Ngày đăng: 22/10/2022, 12:53
Xem thêm: